Literature DB >> 20306253

Apoptosis in leukemias: regulation and therapeutic targeting.

Ismael Samudio1, Marina Konopleva, Bing Carter, Michael Andreeff.   

Abstract

Nearly 25 years after the seminal publication of John Foxton Kerr that first described apoptosis, the process of regulated cell death, our understanding of this basic physiological phenomenon is far from complete [39]. From cardiovascular disease to cancer, apoptosis has assumed a central role with broad ranging therapeutic implications that depend on a complete understanding of this process, yet have also identified an incredibly complex regulatory system that is critical for development and is at the core of many diseases, challenging scientist and clinicians to step into its molecular realm and modulate its circuitry for therapeutic purposes. This chapter will review our understanding of the molecular circuitry that controls apoptosis in leukemia and the pharmacological manipulations of this pathway that may yield therapeutic benefit.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20306253      PMCID: PMC3822431          DOI: 10.1007/978-0-387-69259-3_12

Source DB:  PubMed          Journal:  Cancer Treat Res        ISSN: 0927-3042


  122 in total

1.  Expression and prognostic significance of IAP-family genes in human cancers and myeloid leukemias.

Authors:  I Tamm; S M Kornblau; H Segall; S Krajewski; K Welsh; S Kitada; D A Scudiero; G Tudor; Y H Qui; A Monks; M Andreeff; J C Reed
Journal:  Clin Cancer Res       Date:  2000-05       Impact factor: 12.531

2.  CXCR4 expression and biologic activity in acute myeloid leukemia are dependent on oxygen partial pressure.

Authors:  Michael Fiegl; Ismael Samudio; Karen Clise-Dwyer; Jared K Burks; Zakar Mnjoyan; Michael Andreeff
Journal:  Blood       Date:  2008-10-28       Impact factor: 22.113

3.  Targeting the leukemia microenvironment by CXCR4 inhibition overcomes resistance to kinase inhibitors and chemotherapy in AML.

Authors:  Zhihong Zeng; Yue Xi Shi; Ismael J Samudio; Rui-Yu Wang; Xiaoyang Ling; Olga Frolova; Mark Levis; Joshua B Rubin; Robert R Negrin; Elihu H Estey; Sergej Konoplev; Michael Andreeff; Marina Konopleva
Journal:  Blood       Date:  2008-10-27       Impact factor: 22.113

Review 4.  Targeting Mdm2 and Mdmx in cancer therapy: better living through medicinal chemistry?

Authors:  Mark Wade; Geoffrey M Wahl
Journal:  Mol Cancer Res       Date:  2009-01       Impact factor: 5.852

5.  Synthesis and evaluation of Apogossypol atropisomers as potential Bcl-xL antagonists.

Authors:  Jun Wei; Michele F Rega; Shinichi Kitada; Hongbin Yuan; Dayong Zhai; Prabhakar Risbood; Herbert H Seltzman; Charles E Twine; John C Reed; Maurizio Pellecchia
Journal:  Cancer Lett       Date:  2008-09-07       Impact factor: 8.679

6.  Cyclin-dependent kinase 1 inhibitor RO-3306 enhances p53-mediated Bax activation and mitochondrial apoptosis in AML.

Authors:  Kensuke Kojima; Masaya Shimanuki; Masato Shikami; Michael Andreeff; Hideki Nakakuma
Journal:  Cancer Sci       Date:  2009-03-10       Impact factor: 6.716

7.  A phase I study of the pan bcl-2 family inhibitor obatoclax mesylate in patients with advanced hematologic malignancies.

Authors:  Aaron D Schimmer; Susan O'Brien; Hagop Kantarjian; Joseph Brandwein; Bruce D Cheson; Mark D Minden; Karen Yee; Farhad Ravandi; Francis Giles; Andre Schuh; Vikas Gupta; Michael Andreeff; Charles Koller; Hong Chang; Suzanne Kamel-Reid; Mark Berger; Jean Viallet; Gautam Borthakur
Journal:  Clin Cancer Res       Date:  2008-12-15       Impact factor: 12.531

8.  Full-length hdmX transcripts decrease following genotoxic stress.

Authors:  M Markey; S J Berberich
Journal:  Oncogene       Date:  2008-08-18       Impact factor: 9.867

9.  Structural basis for high-affinity peptide inhibition of p53 interactions with MDM2 and MDMX.

Authors:  Marzena Pazgier; Min Liu; Guozhang Zou; Weirong Yuan; Changqing Li; Chong Li; Jing Li; Juahdi Monbo; Davide Zella; Sergey G Tarasov; Wuyuan Lu
Journal:  Proc Natl Acad Sci U S A       Date:  2009-03-02       Impact factor: 11.205

10.  Concomitant inhibition of Mdm2-p53 interaction and Aurora kinases activates the p53-dependent postmitotic checkpoints and synergistically induces p53-mediated mitochondrial apoptosis along with reduced endoreduplication in acute myelogenous leukemia.

Authors:  Kensuke Kojima; Marina Konopleva; Twee Tsao; Hideki Nakakuma; Michael Andreeff
Journal:  Blood       Date:  2008-07-16       Impact factor: 22.113

View more
  7 in total

1.  TPEN selectively eliminates lymphoblastic B cells from bone marrow pediatric acute lymphoblastic leukemia patients.

Authors:  M Mendivil-Perez; C Velez-Pardo; L M Quiroz-Duque; A Restrepo-Rincon; N A Valencia-Zuluaga; Marlene Jimenez-Del-Rio
Journal:  Biometals       Date:  2022-05-30       Impact factor: 3.378

2.  Evaluation of apoptosis induction by concomitant inhibition of MEK, mTOR, and Bcl-2 in human acute myelogenous leukemia cells.

Authors:  Weiguo Zhang; Vivian R Ruvolo; Chen Gao; Liran Zhou; William Bornmann; Twee Tsao; Wendy D Schober; Paul Smith; Sylvie Guichard; Marina Konopleva; Michael Andreeff
Journal:  Mol Cancer Ther       Date:  2014-04-16       Impact factor: 6.261

3.  Analysis of the interplay between all-trans retinoic acid and histone deacetylase inhibitors in leukemic cells.

Authors:  Katrin Noack; Nisintha Mahendrarajah; Dorle Hennig; Luisa Schmidt; Florian Grebien; Dagmar Hildebrand; Markus Christmann; Bernd Kaina; Andreas Sellmer; Siavosh Mahboobi; Katharina Kubatzky; Thorsten Heinzel; Oliver H Krämer
Journal:  Arch Toxicol       Date:  2016-11-02       Impact factor: 5.153

4.  Characterization of p190-Bcr-Abl chronic myeloid leukemia reveals specific signaling pathways and therapeutic targets.

Authors:  Shady Adnan-Awad; Daehong Kim; Helena Hohtari; Komal Kumar Javarappa; Tania Brandstoetter; Isabella Mayer; Swapnil Potdar; Caroline A Heckman; Soili Kytölä; Kimmo Porkka; Eszter Doma; Veronika Sexl; Matti Kankainen; Satu Mustjoki
Journal:  Leukemia       Date:  2020-11-09       Impact factor: 11.528

5.  Low expression of PP2A regulatory subunit B55α is associated with T308 phosphorylation of AKT and shorter complete remission duration in acute myeloid leukemia patients.

Authors:  P P Ruvolo; Y H Qui; K R Coombes; N Zhang; V R Ruvolo; G Borthakur; M Konopleva; M Andreeff; S M Kornblau
Journal:  Leukemia       Date:  2011-06-10       Impact factor: 11.528

6.  Synergistic suppression effect on tumor growth of acute myeloid leukemia by combining cytarabine with an engineered oncolytic vaccinia virus.

Authors:  Jiamin Peng; Shibing Wang; Weimin Fan; Shuangshuang Li; Yi Wu; Xiaozhou Mou; Jianchao Wang; Xiangmin Tong
Journal:  Onco Targets Ther       Date:  2018-10-15       Impact factor: 4.345

7.  Phosphorylation of GSK3α/β correlates with activation of AKT and is prognostic for poor overall survival in acute myeloid leukemia patients.

Authors:  Peter P Ruvolo; YiHua Qiu; Kevin R Coombes; Nianxiang Zhang; E Shannon Neeley; Vivian R Ruvolo; Numsen Hail; Gautam Borthakur; Marina Konopleva; Michael Andreeff; Steven M Kornblau
Journal:  BBA Clin       Date:  2015-07-23
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.